News

Peginterferon beta-1a, a pegylated form of interferon designed to maintain biologic effects in the body for longer periods, is being evaluated against CinnaGen’s interferon beta-1a formulation, CinnoVex.

The paradigm-shifting evidence of the link between MS and EBV does not exist in isolation. In fact, the relationship has been suspected for more than 40 years, and evidence therein has been accumulating over the past 2 decades.

In a bidirectional Mendelian randomization analysis, findings revealed an association with obstructive sleep apnea and severe COVID-19 that were suggestive of a causal relationship.

The codirector of the ALS Center at Washington University School of Medicine detailed the reasons for hope within the ALS space and the promising innovations in the coming future. [WATCH TIME: 4 minutes]

A sleep study on adolescents and their insomnia symptoms showed that those with a shorter sleep duration experienced deficient executive functions in daily life.

The associate professor of neurology at the Cleveland Clinic Lerner College of Medicine provided perspective on how the clinical community can improve trials for multiple sclerosis that help improve treatment decisions. [WATCH TIME: 4 minutes]

The president of the International Neuropalliative Care Society provided perspective on the growth of the field of neuropalliative care, the organization’s role, and how clinicians are overcoming current barriers in place.

NRTX-1001, an injectable suspension of high-purity inhibitory neurons, is currently being assessed in a phase 1/2 trial that includes a dose-escalation period comprising of 10 individuals with mesial temporal lobe epilepsy.

The postdoctoral researcher and health psychologist at King's College, London spoke at ECTRIMS 2022 about the most important aspect for improving fatigue in MS. [WATCH TIME: 4 minutes]

Compared with conventional treatments, which included routine pharmaceutical treatments or occupational therapy without exercise, aquatic therapy showed several benefits in physical, cognitive, and psychosocial fatigue for patients with MS.

The president of the International Neuropalliative Care Society discussed the area in which neuropalliative has expanded and improved, as well as the potential in the coming years. [WATCH TIME: 2 minutes]

Fatigue, although not immediately visible, is among the most debilitating symptoms of multiple sclerosis, affecting not only patients' day-to-day functioning but their quality of life.

The professor of neurology at Washington University in St. Louis offered an overview of the State of the Science Summit that was held on November 3, 2022, featuring a panel of expert clinicians. [WATCH TIME: 3 minutes]

Nearly 95% of patients treated with vidofludimus calcium were free from 12-week confirmed disability worsening events at week 96 of the open-label extension trial.

The executive vice principal of advocacy and healthcare access at the National MS Society spoke about the implementation of the Inflation Reduction Act and how clinicians may use health navigator services to advocate for their patients with MS. [WATCH TIME: 4 minutes]

Cognitive and other symptoms in multiple sclerosis can be invisible—meaning not readily observed in the individual. However, their impact on a patient’s life can be obvious.

The president of the International Neuropalliative Care Society provided an overview of the organization’s recently concluded conference and the significance of the growth of neuropalliative care. [WATCH TIME: 6 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Over a 12-week treatment period, treatment with continuous subcutaneous carbidopa/levodopa resulted in significantly greater increase in ON time and reduced OFF time, while demonstrating a safe profile.

The executive vice principal of advocacy and healthcare access at the National MS Society spoke about the role of the National MS Society with patient advocacy and the Inflation Reduction Act of 2022. [WATCH TIME: 5 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neuromuscular disorders.

ACU193, an antibody developed based on its selectivity for soluble amyloid-ß oligomers, is currently being assessed in a phase 1 trial, with a potential phase 2/3 trial in the near future.

Neurology News Network for the week ending November 19, 2022. [WATCH TIME: 3 minutes]

Through a culmination of previous research, the International Advisory Committee on Clinical Trials in Multiple Sclerosis suggests that multiple sclerosis disability progression is not caused by a single uniform disease mechanism but a combination of several mechanisms that play out variably over time.

The chief of neurology and codirector of the neuroscience Center at the Children's Hospital of Philadelphia spoke at ECTRIMS 2022 about the difference in conversation for therapies between pediatric patients and adult patients with MS. [WATCH TIME: 5 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 18, 2022.

Compared with placebo, a greater proportion of patients on rituximab met the primary end point of minimal disease manifestations at 16 weeks, and demonstrated favorable results on several secondary end points.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with George Small, MD. [LISTEN TIME: 33 minutes]

Darina Petrovsky, PhD, RN, assistant professor, Rutgers University, spoke about her current study focused on developing a music-based application for people with dementia and their caregivers who have trouble sleeping.

The chief of neurology and codirector of the neuroscience Center at the Children's Hospital of Philadelphia spoke at ECTRIMS 2022 about how her patients with pediatric MS have been inspirational to her in her practice. [WATCH TIME: 4 minutes]